Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$77,756.00+1.30%ETH$2,291.85+1.71%GOLD$3,940.20-0.74%OIL$96.76+0.31%
Smart Investors Daily
SID Premium
Voyager Therapeutics, Inc. logo

NASDAQ · VYGR

Voyager Therapeutics, Inc.

Healthcare · Biotechnology

$1.78

Up+$0.05 (+2.81%)

Updated Nov 3, 2026, 10:10 PM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
245.15M
P/E ratio
-2.05
Dividend yield
0.00%
52-week range
$1.68 – $5.48
Volume
1.19M
Avg. volume
645.37K

Price performance · VYGR

VYGR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

VYGR closed at $1.78 after 21 trading sessions, down 27.64% for the selected period.

Last close
$1.78
Period change
-27.64%
Period low
$1.72
Period high
$2.47
Daily close
View OHLC price history
VYGR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$1.74$1.80$1.71$1.781.19M
Oct 30, 2026$1.75$1.76$1.675$1.72878.83K
Oct 29, 2026$1.86$1.90$1.745$1.76659.89K
Oct 28, 2026$1.73$1.85$1.7029$1.841.14M
Oct 27, 2026$1.76$1.81$1.72$1.731.27M
Oct 26, 2026$1.77$1.78$1.71$1.751.66M
Oct 23, 2026$1.82$1.84$1.74$1.741.05M
Oct 22, 2026$2.03$2.05$1.75$1.861.3M
Oct 21, 2026$2.02$2.16$1.97$2.02935.82K
Oct 20, 2026$2.05$2.29$2.015$2.191.13M
Oct 19, 2026$1.93$2.09$1.885$2.051.26M
Oct 16, 2026$2.05$2.05$1.89$1.90573.51K
Oct 15, 2026$2.00$2.10$2.00$2.06719.35K
Oct 14, 2026$2.13$2.1699$1.985$2.011.19M
Oct 13, 2026$2.24$2.26$2.14$2.151.06M
Oct 12, 2026$2.46$2.47$2.25$2.27967.39K
Oct 9, 2026$2.36$2.515$2.35$2.45694.39K
Oct 8, 2026$2.44$2.46$2.33$2.37932.32K
Oct 7, 2026$2.44$2.50$2.41$2.47763.23K
Oct 6, 2026$2.46$2.495$2.41$2.46617.75K
Oct 5, 2026$2.43$2.55$2.39$2.461.39M

Latest VYGR news

The latest Smart Investors Daily articles mentioning VYGR.

Stock researchCompany · Overview

VYGR research

Overview

Company profile and research snapshot.

Company profile

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$14.40
Implied upside
—
Analysts
18
VYGR recent ratings
DateFirmRatingTarget
Aug 10, 2026HC Wainwright & Co.Buy—
Mar 17, 2026HC Wainwright & Co.Buy—
Nov 12, 2025HC Wainwright & Co.Buy—
Sep 15, 2025HC Wainwright & Co.Buy—
Aug 7, 2025WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager’s investigational gene therapy designed to lower tau production in the brain, and VY7523, the C

Yahoo · Oct 21, 2026

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to remain CEO through initial acute safety data with VY1706, anticipated in Q1 2027 pending enrollment, and to subsequently continue as a member of Voyager’s Board of Directors - LEXINGTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By